Five Prime Therapeutics Inc. (NASDAQ:FPRX) traded up 4.2% during trading on Wednesday . The company traded as high as $47.46 and last traded at $46.80, with a volume of 344,738 shares trading hands. The stock had previously closed at $44.90.

A number of equities research analysts have recently commented on the company. Credit Suisse Group AG restated a “buy” rating on shares of Five Prime Therapeutics in a research report on Tuesday, July 12th. BMO Capital Markets assumed coverage on Five Prime Therapeutics in a report on Tuesday, April 12th. They issued a “market perform” rating and a $50.00 price objective on the stock. Zacks Investment Research upgraded Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Tuesday, April 5th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $48.00 price objective on shares of Five Prime Therapeutics in a report on Thursday, May 19th. Finally, Leerink Swann reiterated a “buy” rating and issued a $45.00 price objective on shares of Five Prime Therapeutics in a report on Friday, July 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $45.67.

The firm has a market cap of $1.24 billion and a price-to-earnings ratio of 5.20. The firm has a 50-day moving average price of $42.61 and a 200-day moving average price of $39.54.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.22. During the same period in the prior year, the business earned ($0.44) EPS. The company had revenue of $6.50 million for the quarter, compared to analysts’ expectations of $5.26 million. The business’s revenue for the quarter was up 51.2% on a year-over-year basis. On average, equities research analysts predict that Five Prime Therapeutics Inc. will post ($2.35) earnings per share for the current fiscal year.

In other news, CFO Marc Belsky sold 34,102 shares of the firm’s stock in a transaction on Friday, April 22nd. The shares were sold at an average price of $50.00, for a total value of $1,705,100.00. Following the transaction, the chief financial officer now owns 88,410 shares of the company’s stock, valued at approximately $4,420,500. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Franklin M. Berger bought 5,000 shares of the business’s stock in a transaction dated Friday, April 22nd. The stock was acquired at an average cost of $49.47 per share, for a total transaction of $247,350.00. Following the purchase, the director now owns 81,980 shares in the company, valued at approximately $4,055,550.60. The disclosure for this purchase can be found here.

Several institutional investors have modified their holdings of the stock. Marshall Wace LLP increased its position in shares of Five Prime Therapeutics by 43.0% in the fourth quarter. Marshall Wace LLP now owns 237,141 shares of the company’s stock worth $9,841,000 after buying an additional 71,262 shares in the last quarter. GSA Capital Partners LLP increased its position in shares of Five Prime Therapeutics by 10.9% in the fourth quarter. GSA Capital Partners LLP now owns 72,200 shares of the company’s stock worth $2,996,000 after buying an additional 7,086 shares in the last quarter. EAM Investors LLC acquired a new position in shares of Five Prime Therapeutics during the fourth quarter worth approximately $1,549,000. ProShare Advisors LLC increased its position in shares of Five Prime Therapeutics by 16.9% in the fourth quarter. ProShare Advisors LLC now owns 25,418 shares of the company’s stock worth $1,055,000 after buying an additional 3,682 shares in the last quarter. Finally, Oxford Asset Management acquired a new position in shares of Five Prime Therapeutics during the fourth quarter worth approximately $1,241,000.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.